Chargement en cours...
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...
Enregistré dans:
| Publié dans: | Onco Targets Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966750/ https://ncbi.nlm.nih.gov/pubmed/27524910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84153 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|